152 related articles for article (PubMed ID: 27798769)
1. Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
Kutoh E; Murayama T; Wada A; Hirate M
Drugs R D; 2016 Dec; 16(4):369-376. PubMed ID: 27798769
[TBL] [Abstract][Full Text] [Related]
2. Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes.
Kutoh E; Wada A; Murayama T; Hayashi J
Drugs R D; 2018 Dec; 18(4):309-315. PubMed ID: 30324549
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
Kutoh E; Wada A; Murayama T; Takizawa Y
Drugs R D; 2017 Jun; 17(2):313-320. PubMed ID: 28285448
[TBL] [Abstract][Full Text] [Related]
4. REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAÏVE SUBJECTS WITH TYPE 2 DIABETES.
Kutoh E; Wada A; Hayashi J
Endocr Pract; 2018 Dec; 24(12):1063-1072. PubMed ID: 30289315
[TBL] [Abstract][Full Text] [Related]
5. Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.
Kutoh E; Wada A; Murayama T; Hirate M
Drug Res (Stuttg); 2016 Jul; 66(7):345-50. PubMed ID: 27056638
[TBL] [Abstract][Full Text] [Related]
6. Link between serum uric acid and pancreatic beta-cell function in drug naïve subjects with type 2 diabetes treated with sitagliptin.
Kutoh E; Wada A; Kuto AN; Hayashi J; Kurihara R
Hosp Pract (1995); 2021 Apr; 49(2):71-78. PubMed ID: 33191818
[No Abstract] [Full Text] [Related]
7. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Kashiwagi A; Sakatani T; Nakamura I; Akiyama N; Kazuta K; Ueyama E; Takahashi H; Kosakai Y
Endocr J; 2018 Jul; 65(7):693-705. PubMed ID: 29848902
[TBL] [Abstract][Full Text] [Related]
8. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
Kutoh E; Wada A; Terayama S
Clin Drug Investig; 2016 Oct; 36(10):809-18. PubMed ID: 27352309
[TBL] [Abstract][Full Text] [Related]
9. Regulations of Free Fatty Acids and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
Kutoh E; Kuto AN; Wada A; Kurihara R; Kojima R
Drug Res (Stuttg); 2022 Feb; 72(2):86-93. PubMed ID: 34729722
[TBL] [Abstract][Full Text] [Related]
10. Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Sugimoto K; Abe I; Minezaki M; Takashi Y; Ochi K; Fujii H; Ohishi H; Yamao Y; Kudo T; Ohe K; Abe M; Ohnishi Y; Shinagawa T; Mukoubara S; Kobayashi K
Drug Discov Ther; 2019; 13(6):322-327. PubMed ID: 31956230
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Adipose Tissue Insulin Resistance and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
Kutoh E; Kuto AN; Ozawa E; Kurihara R; Akiyama M
Drug Res (Stuttg); 2023 Jun; 73(5):279-288. PubMed ID: 36882112
[TBL] [Abstract][Full Text] [Related]
12. Link between body weight changes and metabolic parameters in drugs naïve subjects with type 2 diabetes treated with canagliflozin monotherapy.
Kutoh E; Wada A; Kuto AN; Hayashi J; Kurihara R
Hosp Pract (1995); 2020 Mar; 48(2):68-74. PubMed ID: 32098545
[TBL] [Abstract][Full Text] [Related]
13. Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Tanaka M; Yamakage H; Inoue T; Odori S; Kusakabe T; Shimatsu A; Satoh-Asahara N
Intern Med; 2020; 59(5):601-609. PubMed ID: 32115517
[TBL] [Abstract][Full Text] [Related]
14. Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties.
Kutoh E; Kaneoka N; Hirate M
Endocr Res; 2015; 40(2):88-96. PubMed ID: 25208188
[TBL] [Abstract][Full Text] [Related]
15. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
Diabetes Obes Metab; 2019 Aug; 21(8):1990-1995. PubMed ID: 30993861
[TBL] [Abstract][Full Text] [Related]
16. Diverse Strategies for Modulating Insulin Resistance: Causal or Consequential Inference on Metabolic Parameters in Treatment-Naïve Subjects with Type 2 Diabetes.
Kutoh E; Kuto AN; Okada R; Akiyama M; Kurihara R
Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929608
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.
Tsurutani Y; Nakai K; Inoue K; Azuma K; Mukai S; Maruyama S; Iizuka T; Matsuzawa Y; Saito J; Omura M; Nishikawa T
Diabetes Obes Metab; 2018 Nov; 20(11):2675-2679. PubMed ID: 29893003
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
[TBL] [Abstract][Full Text] [Related]
20. Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study.
Tobe K; Maegawa H; Tabuchi H; Nakamura I; Uno S
J Diabetes Investig; 2019 Sep; 10(5):1262-1271. PubMed ID: 30719865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
